PLAU: Urokinase-type plasminogen activator
Serine protease that cleaves the inactive precursor plasminogen at a specific Arg-Val peptide bond, converting it into active plasmin.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PLAU, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide 1
The landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Urokinase | Approved | Microbix Biosystems | Protein or peptide | Exogenous proteinUrokinase-type plasminogen activator exogenous protein | 20 |
Open trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.| Intravenous Thrombolysis, Endovascular Treatment, or Bridging Therapy for Medium Vessel Occlusion Stroke Within 24 Hours | Urokinase | Phase 3 | Not yet recruiting | The First Affiliated Hospital of University of Science and Technology of China | Nov 12, 2026 |
| Evaluation of [⁶⁸Ga/¹⁷⁷Lu]HT547: Safety, Biodistribution, and Dosimetry in Solid Tumors | Urokinase | Early phase 1 | Not yet recruiting | Hua Pang | Jun 10, 2026 |
| Early Lumbar Drainage for Intraventricular Hemorrhage | Urokinase | Not applicable | Not yet recruiting | Second Affiliated Hospital of Nanchang University | Jun 4, 2026 |
| Pro-urokinase for Extended-Window Posterior Circulation Stroke | Urokinase | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | Jun 1, 2026 |
| STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism | Urokinase | — | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | May 22, 2026 |
| Role of Medical Thoracoscopy in Pleural Infection (PROMPT Trial) | Urokinase | Not applicable | Not yet recruiting | Università Politecnica delle Marche | Apr 24, 2026 |
| TrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage | Urokinase | Not applicable | Recruiting | Xuanwu Hospital, Beijing | Sep 23, 2025 |
| Timing and Outcomes of Recovery After intraCerebral Hemorrhage | Urokinase | — | Recruiting | Xuanwu Hospital, Beijing | Sep 10, 2025 |
Diseases most associated with it
Open Targets association score, 0 to 1; all associations- Quebec platelet disorder
- 0.62
- Abdominal aortic aneurysm
- 0.52
- Recurrent thrombophlebitis
- 0.37
- Atherosclerosis
- 0.37
- Ischemic stroke
- 0.36
- Psoriasis vulgaris
- 0.34
- Diabetic foot
- 0.28
- Empyema
- 0.27
- Stroke disorder
- 0.27
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3286, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P00749, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets